Share ownership Altimmune, Inc.

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-09-16 EDT			5-day change	1st Jan Change
7.580 ^USD	-3.81%		+18.81%	-32.62%

09-10	Sector Update: Health Care Stocks Advance Late Afternoon	MT
09-10	Altimmune Shares Jump After Pemvidutide Shows Strong Lean Mass Preservation in Obesity Trial	MT

Share class: Altimmune, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	71,070,951	70,506,260 ( 99.21 %)	0	99.21 %

Major shareholders: Altimmune, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 7.160 %	5,089,027	7.160 %	34 M $
Vanguard Fiduciary Trust Co. 6.904 %	4,906,614	6.904 %	33 M $
State Street Corp. 5.501 %	3,909,286	5.501 %	26 M $
Ameriprise Trust Co. 4.536 %	3,223,997	4.536 %	22 M $
Tang Capital Management LLC 3.869 %	2,750,000	3.869 %	18 M $
Susquehanna Securities LLC 3.110 %	2,210,401	3.110 %	15 M $
Geode Capital Management LLC 2.243 %	1,593,810	2.243 %	11 M $
Morgan Stanley Investment Management, Inc. 1.817 %	1,291,020	1.817 %	9 M $
Knoll Capital Management LP 1.578 %	1,121,524	1.578 %	8 M $
Goldman Sachs Asset Management LP 1.421 %	1,010,149	1.421 %	7 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	42.84%
Other	11.29%
State Street Corp.	5.50%
Individuals	0.77%
Schweizerische Nationalbank	0.20%
Silvercrest Asset Management Group, Inc.	0.15%
Skandinaviska Enskilda Banken AB	0.09%
Corebridge Financial, Inc.	0.05%
Manulife Financial Corp.	0.04%
Unknown	39.08%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	53.70%
United Kingdom	3.32%
France	1.25%
Switzerland	1.22%
Individuals	0.77%
Canada	0.38%
Sweden	0.09%
Luxembourg	0.07%
Ireland	0.06%
Cayman Islands	0.02%
China	0.02%
Norway	0.02%

Based on 1000 largest holdings

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Employees

Sector

Biotechnology & Medical Research

Calendar

2024-09-25 - Annual General Meeting

More about the company